🇪🇺 MET + Vildagliptin Group in European Union

EMA authorised MET + Vildagliptin Group on 25 September 2007

Marketing authorisation

EMA — authorised 25 September 2007

  • Application: EMEA/H/C/000771
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Galvus
  • Indication: Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
  • Status: approved

Read official source →

Other Diabetes approved in European Union

Frequently asked questions

Is MET + Vildagliptin Group approved in European Union?

Yes. EMA authorised it on 25 September 2007.

Who is the marketing authorisation holder for MET + Vildagliptin Group in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.